Streetbeat News

Regulatory

ERAS

Erasca, Inc. announced positive preliminary Phase 1b data for naporafenib plus trametinib in NRASm melanoma, supporting the ongoing Phase 3 SEACRAFT-2 trial. The company is making rapid progress in its RAS targeting franchise and plans to host an investor event.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:11 pm

MOVE

Movano Health is preparing to submit updated responses to the FDA as part of the final review phase for its EvieMED product. A successful submission could bring the company closer to market introduction.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:07 pm

CASI

CASI Pharmaceuticals has received approval from China's NMPA to proceed with a Phase 1/2 study of CID-103 for treating immune thrombocytopenia.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:07 pm

IBM

IBM's Envizi ESG Suite has received FedRAMP authorization, allowing federal agencies to use it for ESG data management and analysis.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:05 pm

PHVS

Pharvaris (NASDAQ:PHVS) is set to present clinical and non-clinical data supporting its HAE development program at the 2024 ACAAI Annual Scientific Meeting. The company is focused on developing oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE).

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:04 pm

MRNS

Marinus Pharmaceuticals has had its shares halted pending news, which could indicate significant developments for the company. Investors should stay alert for updates.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:00 pm

MRNS

Trading for MRNS was halted at 7:55 a.m. ET due to pending news. This indicates that significant information regarding the company is expected to be released soon, which could impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:55 am

ACHR

Archer Aviation has expressed approval for the FAA's early release of a Special Federal Aviation Regulation. This development is significant for the company as it may facilitate the advancement of their aviation projects.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:43 am

KURA

Kura Oncology has reported promising preclinical data for its menin inhibitor, ziftomenib, in combination with imatinib for treating advanced gastrointestinal stromal tumors (GIST). The combination showed superior antitumor activity compared to imatinib alone. The FDA has cleared the IND application for ziftomenib, and Kura plans to start a proof-of-concept study in 2025.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:39 am

KYMR

Kymera Therapeutics has started dosing in a Phase 1 trial in the US for KT-621, an oral degrader of STAT6, in healthy adults. Results are expected in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 11:35 am